5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Beclin 1 restrains tumorigenesis through Mcl-1 destabilization in an autophagy-independent reciprocal manner.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Mcl-1 is a unique Bcl-2 family member that plays crucial roles in apoptosis. Apoptosis-unrelated functions of Mcl-1 are however emerging, further justifying its tight regulation. Here we unravel a novel mechanism of Mcl-1 regulation mediated by the haplo-insufficient tumour suppressor Beclin 1. Beclin 1 negatively modulates Mcl-1 stability in a reciprocal manner whereby depletion of one leads to the stabilization of the other. This co-regulation is independent of autophagy and of their physical interaction. Both Beclin 1 and Mcl-1 are deubiquitinated and thus stabilized by binding to a common deubiquitinase, USP9X. Beclin 1 and Mcl-1 negatively modulate the proteasomal degradation of each other through competitive displacement of USP9X. The analysis of patient-derived melanoma cells and tissue samples shows that the levels of Beclin 1 decrease, while Mcl-1 levels subsequently increase during melanoma progression in a significant inter-dependent manner. The identified inverse co-regulation of Beclin 1 and Mcl-1 represents a mechanism of functional counteraction in cancer.

          Related collections

          Author and article information

          Journal
          Nat Commun
          Nature communications
          Springer Nature
          2041-1723
          2041-1723
          Dec 04 2014
          : 5
          Affiliations
          [1 ] Department of Experimental Oncology, European Institute of Oncology, IEO, 20139 Milan, Italy.
          [2 ] 1] Department of Experimental Oncology, European Institute of Oncology, IEO, 20139 Milan, Italy [2] IFOM (Fondazione Istituto FIRC di Oncologia Molecolare) at the IFOM-European Institute of Oncology (IEO) Campus, Via Adamello 16, 20139 Milan, Italy.
          [3 ] Department of Human Pathology and Oncology, University of Siena, 53100 Siena, Italy.
          [4 ] 1] IFOM (Fondazione Istituto FIRC di Oncologia Molecolare) at the IFOM-European Institute of Oncology (IEO) Campus, Via Adamello 16, 20139 Milan, Italy [2] Department of Biosciences, University of Milan, 20100 Milan, Italy.
          [5 ] 1] Department of Experimental Oncology, European Institute of Oncology, IEO, 20139 Milan, Italy [2] Department of Biosciences, University of Milan, 20100 Milan, Italy [3] Drug Development Program, European Institute of Oncology, IEO, 20139 Milan, Italy.
          Article
          ncomms6637
          10.1038/ncomms6637
          25472497
          3790ef1b-6c9a-40cb-858b-a09cff17c5db
          History

          Comments

          Comment on this article